Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34806
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMao, Miaomiao-
dc.contributor.authorMattei, Cristiana-
dc.contributor.authorRollo, Ben-
dc.contributor.authorByars, Sean-
dc.contributor.authorCuddy, Claire-
dc.contributor.authorBerecki, Geza-
dc.contributor.authorHeighway, Jacqueline-
dc.contributor.authorPachernegg, Svenja-
dc.contributor.authorMenheniott, Trevelyan-
dc.contributor.authorApted, Danielle-
dc.contributor.authorJia, Linghan-
dc.contributor.authorDalby, Kelley-
dc.contributor.authorNemiroff, Alex-
dc.contributor.authorMullen, Saul A-
dc.contributor.authorReid, Christopher A-
dc.contributor.authorMaljevic, Snezana-
dc.contributor.authorPetrou, Steven-
dc.date2023-
dc.date.accessioned2024-01-04T04:03:33Z-
dc.date.available2024-01-04T04:03:33Z-
dc.date.issued2023-12-26-
dc.identifier.citationThe Journal of Neuroscience : the Official Journal of the Society for Neuroscience 2023-12-26en_US
dc.identifier.issn1529-2401-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34806-
dc.description.abstractSCN2A encodes NaV1.2, an excitatory neuron voltage-gated sodium channel and a major monogenic cause of neurodevelopmental disorders, including developmental and epileptic encephalopathies (DEE) and autism. Clinical presentation and pharmocosensitivity vary with the nature of SCN2A variant dysfunction and can be divided into gain-of-function (GoF) cases with pre- or peri-natal seizures and loss-of-function (LoF) patients typically having infantile spasms after 6 months of age.We established and assessed patient induced pluripotent stem cell (iPSC) - derived neuronal models for two recurrent SCN2A DEE variants with GoF R1882Q and LoF R853Q associated with early- and late-onset DEE, respectively. Two male patient-derived iPSC isogenic pairs were differentiated using Neurogenin-2 overexpression yielding populations of cortical-like glutamatergic neurons. Functional properties were assessed using patch clamp and multielectrode array recordings and transcriptomic profiles obtained with total mRNA sequencing after 2-4 weeks in culture.At 3 weeks of differentiation, increased neuronal activity at cellular and network levels was observed for R1882Q iPSC-derived neurons. In contrast, R853Q neurons showed only subtle changes in excitability after 4 weeks and an overall reduced network activity after 7 weeks in vitro Consistent with the reported efficacy in some GoF SCN2A patients, phenytoin (sodium channel blocker) reduced the excitability of neurons to the control levels in R1882Q neuronal cultures. Transcriptomic alterations in neurons were detected for each variant and convergent pathways suggested potential shared mechanisms underlying SCN2A DEE.In summary, patient iPSC-derived neuronal models of SCN2A GoF and LoF pathogenic variants causing DEE show specific functional and transcriptomic in vitro phenotypes.Significance statement SCN2A encodes one of the major brain voltage-gated sodium channels, NaV1.2, and is a major monogenic cause of neurodevelopmental disorders, including severe infantile epilepsy and autism. SCN2A pathogenic variants cause either gain or loss of channel function, which correlates well with the clinical phenotype. Gain of function variants are associated with early-onset seizures with or without developmental delay, whereas loss of function results in late-onset severe epilepsy and/or autism. We used patient-derived induced pluripotent stem cells to generate neuronal cultures for two recurring SCN2A variants causing early and late seizure onset epilepsy. Identified electrophysiological and transcriptome changes compared to the isogenic control lines can be correlated with the distinguishable clinical phenotype.en_US
dc.language.isoeng-
dc.titleDistinctive in vitro phenotypes in iPSC-derived neurons from patients with gain- and loss-of-function SCN2A developmental and epileptic encephalopathy.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleThe Journal of Neuroscience : the Official Journal of the Society for Neuroscienceen_US
dc.identifier.affiliationFlorey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, VIC 3052, Australia.;Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC 3052, Australia.en_US
dc.identifier.affiliationMurdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC 3052, Australia.en_US
dc.identifier.affiliationRogcon Biosciences, Miami Beach, Florida, USA.;Praxis Precision Medicines, Inc., Cambridge, MA 02142, USA.en_US
dc.identifier.affiliationAustin Healthen_US
dc.identifier.doi10.1523/JNEUROSCI.0692-23.2023en_US
dc.type.contentTexten_US
dc.identifier.pubmedid38148154-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptEpilepsy Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Nov 18, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.